These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 11737083)

  • 1. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.
    Jacobs MR
    Clin Microbiol Infect; 2001 Nov; 7(11):589-96. PubMed ID: 11737083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How can we predict bacterial eradication?
    Jacobs MR
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
    Reed MD
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
    Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
    J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 in Vietnam.
    Van PH; Binh PT; Minh NH; Morrissey I; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i93-102. PubMed ID: 27048586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bacterial resistance and pharmacodynamics as the basis for prescribing antibiotics in respiratory infections].
    Aguado-García JM; Martín-Herrero JE; Lumbreras-Bermejo C
    Enferm Infecc Microbiol Clin; 2004 Apr; 22(4):230-7. PubMed ID: 15056440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections.
    Andes D
    Curr Opin Infect Dis; 2001 Apr; 14(2):165-72. PubMed ID: 11979128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies.
    Owens RC; Shorr AF
    Am J Health Syst Pharm; 2009 Jun; 66(12 Suppl 4):S23-30. PubMed ID: 19502225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy.
    Craig WA
    Respir Med; 2001 Jun; 95 Suppl A():S12-9; discussion S26-7. PubMed ID: 11419669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic susceptibility in Streptococcus pneumoniae, Haemophilus influenzae and Streptococcus pyogenes in Pakistan: a review of results from the Survey of Antibiotic Resistance (SOAR) 2002-15.
    Zafar A; Hasan R; Nizamuddin S; Mahmood N; Mukhtar S; Ali F; Morrissey I; Barker K; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i103-9. PubMed ID: 27048578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of oral beta-lactam antibiotics as a two-dimensional approach to their efficacy.
    Auckenthaler R
    J Antimicrob Chemother; 2002 Jul; 50 Suppl():13-7. PubMed ID: 12077155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae.
    Jacobs MR
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():18-27. PubMed ID: 14759230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia.
    Ohno A; Ishii Y; Kobayashi I; Yamaguchi K
    J Infect Chemother; 2007 Oct; 13(5):296-301. PubMed ID: 17982717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 and 2013-14 in China.
    Hu F; Zhu D; Wang F; Morrissey I; Wang J; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i33-43. PubMed ID: 27048581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The crisis of resistant pathogens in respiratory tract infections--use of pharmacodynamic principles.
    Palavecino EL
    Am J Manag Care; 2001 Jun; 7(6 Suppl):S170-7. PubMed ID: 11424585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro pharmacokinetic and pharmacodynamic evaluation of S-013420 against Haemophilus influenzae and Streptococcus pneumoniae.
    Homma T; Hori T; Ohshiro M; Maki H; Yamano Y; Shimada J; Kuwahara S
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4300-5. PubMed ID: 20660692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing antimicrobial susceptibility patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Castanheira M; Gales AC; Pignatari AC; Jones RN; Sader HS
    Microb Drug Resist; 2006; 12(2):91-8. PubMed ID: 16922623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.
    Andes D; Anon J; Jacobs MR; Craig WA
    Clin Lab Med; 2004 Jun; 24(2):477-502. PubMed ID: 15177850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance.
    Craig WA
    Am J Med; 2004 Aug; 117 Suppl 3A():16S-22S. PubMed ID: 15360093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.